论文部分内容阅读
T淋巴细胞在特异性抗肿瘤免疫应答中起关键作用。肿瘤浸润淋巴细胞(TIL)中富含肿瘤反应性T细胞,体外培养TIL并回输给带瘤宿主,可提高临床免疫治疗效果。但是TIL仍具有高度的异质性,只有从中找到并分离出那些在肿瘤抗原驱动下发生寡克隆扩增T细胞,才有希望在特异并性治疗方面取得突破。国外九十年代起采用分子生物学技术确定TIL中发生寡克隆扩增T细胞的TCR V区基因的特定结构,为肿瘤特异性T细胞免疫治疗开拓了新的前景。本文即是跟踪国外的这一进展,应用定量PCR技术,分析人体肾细胞癌(RCC)TIL的TCR受体谱结构及相应的寡克隆偏移格局。
T lymphocytes play a key role in the specific anti-tumor immune response. Tumor infiltrating lymphocytes (TIL) is rich in tumor-reactive T cells, cultured TIL and returned to the tumor-bearing host, can improve the clinical immunotherapy. However, TIL is still highly heterogeneous. Only through finding and isolating oligoclonal T-cells that are driven by tumor antigens can we hope to achieve a breakthrough in specific congenital therapy. In the 1990s, molecular biology techniques were used to determine the specific structure of TCR V region gene in oligo-cloned T cells in TIL, which opens up new prospects for tumor-specific T cell immunotherapy. This article is to follow the progress of foreign countries, the use of quantitative PCR technology, analysis of human renal cell carcinoma (TCC) TCR receptor TCR receptor structure and the corresponding oligoclonal shift pattern.